The need to manage the risk of thromboembolism in COVID-19 patients
The need to manage the risk of thromboembolism in COVID-19 patients
复制标题
DOI：
10.1016/j.jvs.2020.05.015
复制
发表时间：
2020-09-01
影响因子：
4.3
通讯作者：
Harky, Amer
中科院分区：
文献类型：
--
作者：
Khan, Inayat Hussain;Savarimuthu, Sugeevan;Harky, Amer
2019年12月，COVID-19首次在中国湖北省武汉市出现。它被认为是人畜共患疾病，已被命名为SARS-CoV-2 (COVID-19)，并迅速传播。截至2020年4月20日，全球共记录了10240万例病例。与COVID-19相关的炎症过程、细胞因子风暴和肺损伤会增加患者血栓形成的风险。目前尚不确定COVID-19患者血栓形成事件的总发生率。那些患有更严重疾病和具有其他风险因素的人，包括年龄增长、男性、肥胖、癌症、合并症和入住重症监护病房，发生这些事件的风险更高。然而，关于如何管理COVID-19患者的这些风险，国际上几乎没有指导。在本文中，我们探讨了目前的证据和理论，围绕这些独特的患者血栓形成，并反思从我们中心的经验。
COVID-19 first appeared in Wuhan, Hubei Province, China, in December 2019. Thought to be of zoonotic origin, it has been named SARS-CoV-2 (COVID-19) and has spread rapidly. As of April 20, 2020, there have been >2.4 million cases recorded worldwide. The inflammatory process, cytokine storm, and lung injury that are associated with COVID-19 can put patients at an increased risk of thrombosis. The total incidence of thrombotic events in COVID-19 patients is currently uncertain. Those with more severe disease and with other risk factors, including increasing age, male sex, obesity, cancer, comor-bidities, and intensive care unit admission, are at higher risk of these events. However, there is little international guidance on managing these risks in COVID-19 patients. In this paper, we explore the current evidence and theories surrounding thrombosis in these unique patients and reflect on experience from our center.